Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments

Официальное название

Implementation and Impact of Multidisciplinary Medication Review in Surgery Departments on Medication Management of Elderly Patients

Обзор

The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.

Вмешательства

• Другое Mutlidisciplinary medication Review (MMR)
  The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community
• Другое Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up
  Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Community fo

Первичные конечные точки

• Change in iatrogenic drug risk in intervention groups versus control group [Срок оценки: 3 months after hospitalization]

Вторичные конечные точки (12)

• Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups [Срок оценки: Hospital discharge (maximum 30 days)]
• Number of potentially inappropriate medications per patient in each group [Срок оценки: Hospital discharge (maximum 30 days)]
• Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent [Срок оценки: 3 months after hospital discharge]
• Number of potentially inappropriate medications per patient in each group [Срок оценки: 3 months after hospital discharge]
• Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2) [Срок оценки: Hospital discharge (maximum 30 days)]
• Time required for ransmitting multidisciplinary correspondence documents in B2 group [Срок оценки: Hospital discharge (maximum 30 days)]
• Number of multidisciplinary correspondence documents sent to the community acotors in B2 group [Срок оценки: Hospital discharge (maximum 30 days)]
• Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group [Срок оценки: Hospital discharge (maximum 30 days)]
• Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group [Срок оценки: Hospital discharge (maximum 30 days)]
• Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group [Срок оценки: 2 months post discharge]
• Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2 [Срок оценки: 2 months post hospital discharge]
• Rate of patients with at least one rehospitalization in each group [Срок оценки: 3 months after hospital discharge]

Критерии участия

Критерии включения

• The patient (or their representative) has given his consent and signed the consent form.
• The patient is affiliated to a health insurance programme.
• The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
• The patient is available for a follow-up of 3 months.
• The patient is hospitalized in the surgery department.
• Patient with a Trivalle score greater than or equal to 2 (≥).
• Patient living in a nursing home or going back home after hospitalization.

Критерии исключения

• The subject is participating in another category I interventional study.
• The subject is in an exclusion period determined by another study.
• The subject is under safeguard of justice.
• It is not possible to give the patient (or his/her trusted-person) informed information.
• Palliative care

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Другое

Центры проведения

Франция · 4 центра

• Chu de Grenoble — Grenoble
• CHU de Montpellier — Montpellier
• Nimes University Hospital — Nîmes
• CHU de Toulouse — Toulouse

Идентификаторы

NCT: NCT03827031 · NIMAO/2017-02/JMK-01

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗